You schedule a routine appointment. The visit lasts twelve minutes. A few questions, a quick exam, a recommendation, and you’re out the door. A week later, the bill arrives. The number is higher than expected—much higher—and difficult to interpret. There are line items you don’t recognize, codes you don’t understand, and a total that seems disconnected from the brief encounter you remember.

You call. After navigating a series of prompts, you reach someone who explains that the price reflects not just the visit, but the system behind it—facility fees, negotiated rates, insurance adjustments. The explanation is clear enough in isolation, but it does not resolve the underlying confusion. The experience was simple, the structure behind it is not.

In another part of the system, a physician moves from room to room on a tightly managed schedule. Each visit is limited. Documentation must be completed in a specific format. Billing codes must align. There is little room to extend a conversation, even when it would help. Nothing about this feels intentionally neglectful. The constraints are understood. Still, something is missing.

Elsewhere, a patient arrives at an emergency department for a non-life-threatening issue. The visit is brief. The treatment is straightforward. Months later, the bill reflects thousands of dollars in charges—most of it attributed not to what was done, but to where it was done. The facility, the staffing model, the overhead. Each component has its own logic. Together, they form a total that feels disconnected from the experience itself.

These moments are familiar. They are discussed often, usually in terms of what has gone wrong. Prices are too high. Care feels rushed. The system appears inefficient, impersonal, and difficult to navigate. The conclusion follows naturally: something is broken.

But this explanation does not hold for long. Because the same system produces some of the most advanced medical technologies in the world. It supports highly specialized care, cutting-edge research, and rapid innovation in areas that were once thought intractable. Treatments that did not exist a decade ago are now routine. Outcomes in certain domains are among the best available anywhere.

Both of these things are true.

And they do not resolve easily into a single explanation.

What appears, at first, as a broken system begins to look different when viewed across a longer span. The difficulty is not that it fails in obvious ways, but that it produces outcomes that seem to contradict one another—high capability alongside high cost, advanced treatment alongside fragmented experience, innovation alongside inefficiency.

This is often attributed to a set of familiar causes. Pharmaceutical companies price aggressively. Insurance companies restrict access. Hospitals charge excessively. Policymakers fail to coordinate effectively. Each of these explanations contains truth. Each can be supported with examples. And yet, none of them, on their own, account for the system as a whole.

Remove one, and the structure does not resolve. It adjusts.

This is the first signal that something else is operating.

⸻

The American healthcare system was not designed as a single, unified structure. It formed over time, through a series of responses to specific conditions.

One of its central features—employer-based insurance—did not begin as a deliberate policy choice. It expanded during the 1940s, when wartime wage controls limited how companies could compete for workers. Unable to offer higher salaries, employers began offering health benefits instead. What started as a workaround became a foundation.

In the decades that followed, additional layers were added rather than replaced. In 1965, public programs such as Medicare and Medicaid were introduced to address populations the private system did not cover. They did not unify the system. They extended it.

Private insurers continued to develop mechanisms to manage risk. Pharmaceutical companies operated within a patent framework that rewarded innovation and exclusivity. Hospitals expanded, then consolidated, to manage increasing scale and cost.

Each of these developments made sense in isolation. Each addressed a real constraint at the time. But none were designed to integrate fully with the others. Over time, they accumulated. What exists now is not a single system, but a convergence of systems—each with its own structure, incentives, and constraints, interacting across scale.

What most people encounter first is not the hospital or the drug company, but the interface that sits between them and everything else.

Insurance.

A bill arrives, but it is not a bill in the usual sense. It lists a price, then another price, then an “allowed amount,” then an adjustment, then a remaining balance. The same procedure can carry different totals depending on the plan, the provider, and whether it is considered in-network or out-of-network. What is being paid is not fixed. It is negotiated.

This is the first point at which the system begins to feel opaque. But the opacity is not accidental. It reflects the role insurance is designed to play.

At its core, insurance exists to manage risk. It pools uncertainty across a large population and distributes the cost of care over time. In a simple system, this function is relatively direct: contributions are collected, care is provided, and costs are covered as they arise.

The American system is not simple.

Instead of a single structure, there are many—private insurers, employer-sponsored plans, public programs, each with its own rules, contracts, and pricing agreements. Hospitals and providers do not set one price for a service. They negotiate different rates with different insurers. What appears on a bill is often a starting point, not a final figure.

This produces a system in which price is not a property of the service itself, but of the relationship between entities. An MRI does not cost a fixed amount. It costs one amount under one plan, another under a different plan, and something else entirely without coverage. The variation is not an error. It is a feature of how the system operates.

From the perspective of the insurer, this complexity has a function. Negotiation allows for cost control. Networks create leverage. Coverage rules manage utilization. Each of these mechanisms is intended to reduce risk and contain expense.

From the perspective of the patient, the same mechanisms appear as friction. Approval processes delay care. Network restrictions limit choice. Pricing remains unclear until after the fact. What is being managed at one level is being experienced as obstruction at another. This is not a contradiction. It is the same structure seen from two positions.

Over time, this layer does not remain separate. It begins to shape the rest of the system.

Providers adjust to it. Billing becomes more detailed. Documentation aligns with reimbursement codes. Entire administrative functions develop to navigate claims, appeals, and compliance. What began as a way to manage risk becomes a framework that influences how care is delivered. A physician does not simply diagnose and treat. They document in a way that can be processed. A hospital does not simply provide services. It structures those services in accordance with how they will be reimbursed. Nothing here is arbitrary. Each step follows from the conditions in place. And once established, it persists.

At scale, this produces a system that is difficult to see all at once. Each interaction makes sense locally. A claim is reviewed. A rate is negotiated. A service is coded. A payment is adjusted. At no single point does the system appear irrational. And yet, when experienced as a whole, it often does.

This is a second signal. The difficulty is not located in any one part. It emerges from how the parts interact.

If we stop here, the system already begins to look less like a single structure and more like a layered process. But insurance is only one layer. Beneath it—and interacting with it—are others that operate according to different incentives.

Hospitals scale care. Pharmaceutical companies develop and price treatments. Intermediaries manage access and distribution. Each of these layers solves a problem. Each introduces new constraints. And none operate in isolation.

⸻

Beneath the insurance layer sits the place where most care is actually delivered.

The hospital.

For many patients, this is where the system becomes most visible—and most confusing. The same procedure can carry dramatically different prices depending on where it is performed. A short emergency visit can result in a bill that far exceeds what was done. A routine scan may cost hundreds in one setting and thousands in another.

At first, this appears arbitrary.

It is not.

Hospitals do not operate as simple service providers. They are complex systems that must maintain staffing, equipment, facilities, compliance, and capacity at all times—whether those resources are being used or not.

An emergency department, for example, must be fully operational around the clock. Specialists must be available. Equipment must be ready. Space must be maintained for events that may or may not occur. The cost of this readiness does not attach cleanly to any one patient encounter. It is distributed across all of them.

This is part of what appears on a bill as a “facility fee.” The treatment may take minutes. The system supporting it does not.

At the same time, hospitals do not charge a single price for that system.

They negotiate.

A large hospital network may agree to one rate with one insurer, another with a different insurer, and something else entirely for an uninsured patient. These rates are not simply reflections of cost. They are shaped by leverage—who has it, who needs access, and how much negotiating power each side brings.

In many regions, that leverage has shifted. Over the past several decades, independent hospitals have consolidated into large systems. In some areas, a small number of networks now control a significant share of available care. This concentration allows them to negotiate higher reimbursement rates, particularly when insurers cannot realistically exclude them from coverage.

From within the system, this appears as strategy. From outside it, it appears as price inflation.

Both are accurate.

There is another layer to this. Hospitals do not receive uniform payment for all patients. Public programs such as Medicare and Medicaid typically reimburse at lower rates than private insurance. To remain viable, hospitals often compensate by charging higher rates to privately insured patients. This creates a form of cross-subsidization. One part of the system absorbs the shortfall of another.

Again, this is not hidden. It is widely understood within the industry. But from the perspective of the patient receiving a bill, it is rarely visible. What appears as a high price for a specific service may reflect a broader balancing of the system.

The logic holds internally. The experience does not.

Over time, these dynamics begin to shape how care is organized. Hospitals expand services that are well reimbursed and reduce those that are not. Specialized procedures—cardiology, orthopedics, oncology—receive investment. Lower-margin services may be consolidated, outsourced, or eliminated. The structure of care adjusts to the structure of payment.

This does not require explicit intent. It follows from reinforcement. What is paid for persists. What is not becomes difficult to sustain.

At this point, the cost question begins to shift. It is no longer only:

Why is this so expensive?

It becomes:

What kind of system produces these prices?

From within each layer, the answer remains coherent.

• The hospital maintains capacity and negotiates rates to sustain operations

• The insurer manages risk and attempts to control costs

• The patient encounters the result as a bill that feels disproportionate

No single step is irrational, but the outcome often feels that way.

And still, this is not the full picture. Because even these prices—high as they are—do not originate entirely within the hospital system. They are influenced by another layer, operating alongside it, shaping both cost and possibility.

⸻

Alongside hospitals—sometimes upstream of them, sometimes independent—sits another part of the system that draws both admiration and scrutiny.

Pharmaceuticals.

This is where some of the most visible contradictions in American healthcare come into focus. Treatments that did not exist a decade ago are now widely available. Conditions once considered untreatable can be managed, delayed, or even reversed. The pace of development, particularly in areas like oncology and immunotherapy, has been rapid.

And yet, the cost of many of these treatments is extraordinarily high. This contrast is often framed in moral terms. Drug companies are accused of price gouging. Patients point to medications—sometimes long established—that cost far more in the United States than in other countries. Insulin is a common example. A drug discovered a century ago, essential for survival, can carry a price that varies dramatically depending on location and coverage.

These criticisms are not without basis. But they are not the full explanation.

Pharmaceutical companies operate within a structure built around patents and exclusivity. A new drug, once approved, is granted a period during which competitors cannot produce a generic equivalent. This window is intended to allow the company to recover the cost of research and development, including the many compounds that never reach market. During this time, pricing power is significant.

From within the system, this has a clear function. Without the possibility of substantial return, the incentive to invest in high-risk, long-horizon research diminishes. The development of a new therapy can take years, sometimes decades, with no guarantee of success. The cost is not limited to what succeeds, but includes what fails along the way.

High prices, in this view, are not simply extraction. They are part of the mechanism that sustains innovation.

At the same time, the structure allows for behavior that extends beyond this justification. Patent protections can be extended through modifications. Pricing can be increased incrementally, particularly for drugs with limited competition. Marketing and distribution strategies can reinforce demand. The system does not distinguish cleanly between what is necessary to support innovation and what is possible because the structure allows it.

Both occur.

There is also a difference between what is listed and what is paid. The “list price” of a drug is often not the final price. Behind the scenes, negotiations take place between manufacturers, insurers, and a set of intermediaries that determine which drugs are covered and at what cost. Rebates are applied. Discounts are negotiated. Formularies are structured to favor certain treatments over others.

This process is not visible to most patients. What they encounter is the portion that remains after these negotiations—often through copays or deductibles tied to the list price rather than the negotiated one. This contributes to the sense that pricing is arbitrary.

It is not arbitrary. But it is difficult to trace.

⸻

At this point, another layer becomes visible. Between the pharmaceutical company that develops a drug and the insurer that covers it sits an intermediary that manages access, pricing, and distribution. These are entities embedded within companies like CVS Health or Cigna.

They are known as pharmacy benefit managers. Most patients do not know they exist.

Pharmacy benefit managers, or PBMs, play a central role in determining which drugs are covered, how they are tiered, and what portion of the cost is borne by the patient. They negotiate rebates from manufacturers in exchange for favorable placement on formularies. They manage networks of pharmacies. They process claims and set reimbursement rates.

At a simple level, these intermediaries appear to function as negotiators—working to secure lower prices on behalf of insurers and patients.

In practice, their role is broader.

They do not only negotiate prices, they influence which drugs are used in the first place. By determining which medications are covered, preferred, or restricted, they shape demand across the system. Manufacturers, in turn, compete for favorable placement—often by offering rebates that are not visible at the point of purchase.

PBMs do not simply broker cost. They shape demand.

What results is not a single price, but a layered one. From within the system, this introduces leverage. From outside it, it introduces another layer of opacity. This is where the structure becomes harder to follow. A manufacturer sets a list price. A PBM negotiates a rebate. An insurer structures coverage. A patient pays a portion that may be based on the original price rather than the discounted one.

Each step has its own logic. Together, they produce a result that is difficult to reconcile with the original service: a medication, prescribed and filled.

Again, no single part of this process appears irrational on its own.

The pharmaceutical company seeks return on investment.

The PBM seeks leverage in negotiation.

The insurer seeks to manage cost and utilization.

Each operates within its own constraints. Each reinforces the others.

At this point, the pattern begins to repeat.

• Prices are high, but not for a single reason

• Profits exist, but are not concentrated in one place

• Innovation advances, even as access becomes uneven

The system produces all of these outcomes at once.

This is where many explanations stop. They identify a target—pharma, insurers, intermediaries—and assign responsibility. And again, there is truth in each of these. But removing one does not resolve the structure. It alters it.

The system does not concentrate cost in one place. It distributes it across layers.

⸻

By now, the outline is becoming clearer.

Insurance manages risk and shapes access.

Hospitals scale care and negotiate price.

Pharmaceutical companies develop treatments within a system that rewards exclusivity.

Intermediaries manage flow, often invisibly.

Each layer solves a problem. Each introduces new constraints.

And none were designed to function as a unified whole.

At scale, this produces a system that is difficult to see clearly from any single position.

For the patient, it appears fragmented and expensive.

For the provider, it appears constrained and procedural.

For the companies within it, it appears structured and necessary.

All of these views are valid.

None are complete.

What remains is to understand why, even when these dynamics are recognized, the system does not easily change. Why solutions that appear obvious at one level fail to resolve the whole.

Even when these dynamics are understood, meaningful change rarely occurs at the scale required to alter the system. Proposals emerge. Prices should be lowered. Access should be expanded. Administrative complexity should be reduced. Each of these has been pursued, in some form, at different points in time. Each has produced results. And yet, the overall structure remains.

This persistence is often attributed to failure—of policy, of leadership, of coordination. But the pattern suggests something else. The system is not simply difficult to change. It is structured to continue.

At each layer, incentives reinforce what already exists. Hospitals expand services that are well reimbursed and protect the revenue streams that sustain them. Insurers refine networks and coverage rules to manage cost within the system as it is. Pharmaceutical companies operate within a framework that rewards exclusivity and return on investment. Intermediaries maintain the processes that justify their role.

None of this requires alignment. Each part responds to its own conditions. Together, they produce a form of stability.

When change is introduced, it does not arrive in an empty space. It enters a system already in motion. A policy aimed at reducing cost in one area shifts pressure to another. Expanding access increases utilization, which raises demand across the system. Limiting pricing power in one segment may reduce investment or redirect it elsewhere. What appears as a solution at one level becomes an adjustment within a larger structure.

This is why reforms often feel partial—because they are. They operate within the system, not outside it.

The Affordable Care Act provides a clear example. It expanded access to care, reduced the number of uninsured, and introduced new protections. It also added new layers of interaction—between insurers, providers, and regulators—within a system that was already complex. The result was not simplification, but accommodation. More people entered the system. The system itself became more intricate.

Both outcomes were real. Neither resolved the underlying structure.

There is also a more visible force at work. Policy does not develop independently of the system it governs. Organizations representing hospitals, insurers, pharmaceutical companies, and other stakeholders participate continuously in shaping legislation. They provide input, propose adjustments, and work to ensure that changes do not undermine the conditions on which they depend.

This is often described as lobbying. It is sometimes framed as an external influence—as though it acts on the system from outside. But it can also be understood as a continuation of the same dynamics already in place.

Each part of the system has something to sustain. When those conditions are threatened, response follows. At the level of policy, that response becomes influence.

This does not require coordination. No single group directs the system. No single decision determines its course. But many actors, operating within their own constraints, act to preserve what allows them to continue. Over time, the structure stabilizes, not because it is optimal, but because it is reinforced.

At this point, the difficulty becomes clearer. The system does not resist change in a direct or visible way. It does not reject reform outright. It absorbs it. Adjusts to it. Integrates it into what already exists.

And in doing so, it remains.

This is a third signal.

What appears to be a series of unresolved problems begins to look like a coherent pattern. The system produces the outcomes it is structured to produce. And when those outcomes are challenged, it adapts in ways that allow the structure to continue.

From within the system, this feels like stagnation or failure. From a wider span, it resembles something else—persistence.

⸻

It is natural, at this point, to look elsewhere. If the American system produces these outcomes—high cost, uneven access, extraordinary capability alongside persistent friction—then the question follows: are other systems structured differently, and do they resolve these tensions more effectively?

They are. But not in a way that eliminates the underlying pattern.

In the United Kingdom, much of healthcare is delivered through a centralized public system. The National Health Service provides care funded through taxation, with pricing largely removed from the point of service. Access is broad. Administrative complexity is reduced. The experience, in many cases, is more coherent.

But the same structure introduces different constraints.

Resources must be allocated centrally. Capacity is finite. When demand exceeds what the system can absorb, delays emerge. Waiting lists extend. Certain forms of care become slower to access—not because they are unavailable, but because they must be distributed across the entire population.

The pressure does not disappear. It shifts.

In Canada, a publicly funded model ensures universal coverage for core services. The system reduces financial barriers at the point of care and simplifies many of the interactions that define the American experience.

But here, too, tradeoffs appear.

Specialized procedures can involve longer wait times. Access to certain advanced treatments may require referral pathways that extend over time. The system remains stable, but less flexible in responding quickly to changes in demand.

Again, the structure holds. But it holds in a different way.

In Germany, a regulated multi-payer system combines elements of public oversight with private participation. Insurance is broadly accessible, pricing is more tightly controlled, and negotiation occurs within a defined framework.

This produces a different balance. Costs are lower than in the United States. Access is relatively strong. Administrative complexity remains, but within more constrained boundaries.

And still, the same pattern is present.

The system must manage cost, distribute care, and maintain capacity. It does so through a different arrangement of incentives, but not without tradeoffs.

Seen together, these systems begin to clarify what the American system does not. There is no single solution to the problem of care. There are only different ways of organizing its constraints.

⸻

The United States system places emphasis on innovation, specialization, and rapid development. It supports a level of technological advancement that is difficult to replicate elsewhere. It also produces higher costs, greater variability, and a more fragmented experience.

Other systems place emphasis on access, cost control, and baseline coverage. They reduce financial barriers and simplify interaction. They also introduce limits—on speed, on availability, on how quickly new developments are integrated.

Each system works. But each works toward a different outcome.

This is the final shift. What appears at first as a uniquely broken system begins to look like a particular expression of a broader pattern.

Different conditions. Different structures. Different results.

The American system is not an exception, it is an example. It shows what happens when multiple systems—insurance, hospitals, pharmaceuticals, policy—develop independently, accumulate over time, and interact at scale without a unifying design. It shows how incentives shape behavior, how behavior becomes structure, and how structure persists. It shows how a system can be highly capable and deeply frustrating at the same time.

From within, the experience remains what it has always been.

A bill that does not match the visit.

A process that is difficult to follow.

A sense that something, somewhere, is not working as it should.

That feeling is not misplaced. But it does not point to a single cause.

The system does not fail in one place. It functions across many. And once seen in this way, the question begins to change. Not how to fix what is broken, but how to understand what is being produced—and why it continues.

⸻

Care is delivered locally. The system is not.

Seen through the Long Span, the system resolves into something more familiar. It forms, not all at once, but through accumulation. Each layer emerges in response to a constraint—access, cost, risk, innovation—and remains in place as new layers are added. Nothing is removed. What exists is extended.

Over time, these layers begin to interact. Incentives shape behavior. Behavior reinforces structure. Structure narrows what can change. What is visible appears fragmented, but the underlying movement remains consistent.

What feels like disorder at the surface reflects coherence at another level. Within the event window, the system appears as a series of failures.

A price that does not make sense.

A delay that should not exist.

A process that seems unnecessarily complex.

Each can be explained locally. None resolve the whole. Across the span, a different pattern comes into view.

The system does not optimize for simplicity.

It stabilizes around what it can sustain.

Different tendencies can be seen operating together.

Activity drives innovation, expansion, and specialization.

Accumulation preserves structure, even as it limits flexibility.

Moments of clarity appear, but do not persist on their own.

These movements overlap, reinforce, and give way in time. The result is not a system that fails to function. It is a system expressing its conditions.

No single actor defines it. Not the hospital, not the insurer, not the pharmaceutical company, not the policymaker. Each operates within a range shaped by incentives, constraints, and reinforcement. What appears through them is not arbitrary. It is patterned.

And so the system continues.

Not because it is optimal.

Not because it is agreed upon.

But because it is sustained.

The question is no longer why it feels broken.

It is:

What does this system produce, given the conditions that remain?

The answer is already visible.

High capability.

High cost.

Fragmented experience.

Persistent complexity.

Not as contradictions. As outcomes.

The system does not resolve them. It holds them together.

Nothing has been simplified.

But something has become clear.

⸻

THE LONG SPAN

The Central Observation

The Condition A twelve-minute visit. A bill that does not match it. A process that is difficult to follow. A sense that something, somewhere, is not working as it should.

The Puzzle The same system produces some of the most advanced medical technologies in the world — and prices, complexity, and fragmentation that feel impossible to justify. Both are true. They do not resolve easily into a single explanation.

The Answer The system does not fail in one place. It functions across many. What appears as disorder at the surface reflects coherence at another level. The system produces the outcomes it is structured to produce.

⸻

How It Formed

Accumulation, Not Design The American healthcare system was not built as a unified structure. It formed through a series of responses to specific conditions. Employer-based insurance expanded during wartime wage controls. Medicare and Medicaid were added to cover populations the private system did not reach. Each layer addressed a real constraint. None were designed to integrate with the others.

What Results Not a single system, but a convergence of systems — each with its own structure, incentives, and constraints, interacting across scale. Nothing has been removed. What exists has only been extended.

⸻

The Layers

Insurance At its core, insurance pools risk across a large population. In practice, it negotiates different rates with different providers, manages utilization through coverage rules, and shapes how care is delivered by determining how it is reimbursed. What is managed at one level is experienced as obstruction at another.

Hospitals A hospital must maintain staffing, equipment, and capacity at all times — whether those resources are being used or not. That cost is distributed across all patient encounters. Prices are not fixed. They are negotiated. Consolidation has shifted leverage toward large networks, allowing higher reimbursement rates. Public program shortfalls are compensated by charging more to privately insured patients. The logic holds internally. The experience does not.

Pharmaceuticals Patents grant exclusivity that allows companies to recover the cost of research — including the many compounds that never reach market. High prices sustain innovation. They also allow for behavior the structure permits but does not require. What is listed is rarely what is paid. Behind the visible price, negotiations between manufacturers, insurers, and intermediaries determine what is covered and at what cost.

Intermediaries Pharmacy benefit managers sit between manufacturers and insurers, negotiating rebates in exchange for formulary placement. They do not simply manage cost — they shape which drugs are used. Their role is largely invisible to patients. What results is not a single price, but a layered one, each step coherent on its own, difficult to reconcile as a whole.

⸻

Why It Persists

Reinforcement At each layer, incentives reinforce what already exists. Hospitals expand well-reimbursed services. Insurers refine coverage rules within the system as it is. Pharmaceutical companies operate within a framework that rewards exclusivity. Intermediaries maintain the processes that justify their role. None of this requires coordination. Each part responds to its own conditions.

Absorption The system does not resist change directly. It absorbs it. A policy aimed at reducing cost in one area shifts pressure to another. Expanding access raises demand across the system. Limiting pricing power in one segment redirects investment elsewhere. What appears as a solution at one level becomes an adjustment within a larger structure.

The Affordable Care Act It expanded access, reduced the uninsured, and introduced new protections. It also added new layers of interaction within a system already complex. More people entered the system. The system became more intricate. Both outcomes were real. Neither resolved the underlying structure.

⸻

Other Systems

United Kingdom Centralized, publicly funded, administratively simpler. The same pressure does not disappear — it shifts. When demand exceeds capacity, delays emerge.

Canada Universal coverage reduces financial barriers. Specialized procedures can involve longer wait times. The system is stable, but less flexible under changing demand.

Germany Regulated multi-payer structure. Costs lower than the United States. Access relatively strong. Administrative complexity remains, within more constrained boundaries.

What This Shows There is no single solution to the problem of care. There are only different ways of organizing its constraints. Each system works — toward a different outcome.

⸻

Closing Note

The American system is not an exception. It is an example — of what happens when multiple systems develop independently, accumulate over time, and interact at scale without a unifying design.

The system does not optimize for simplicity. It stabilizes around what it can sustain. High capability, high cost, fragmented experience, and persistent complexity are not contradictions. They are outcomes.

The system does not resolve them. It holds them together.